Hamilton, Ont. August 24, 2011—McMaster University officially unveiled today its newly expanded Nuclear Research Building, a new cyclotron facility and improvements to the McMaster Nuclear Reactor (MNR) Building: facilities which are now available for the world’s leading nuclear scientists and engineers.
Nuclear sciences and engineering received $22-million from the federal and provincial governments in 2009 as part of the Knowledge Infrastructure Program. The money was used to upgrade physical infrastructure, expand isotope research and production capacity, and enhance research and education facilities for the nuclear industry and health care sectors.
“This investment has reinforced McMaster’s position as one of the world’s top nuclear science and engineering research universities and significantly enhances our innovation and education goals,” says Patrick Deane, president of McMaster. “This will also enable the university and our researchers to make a real difference in the lives of many people within our own community.”
A new facility houses a 10-ton, $2-million cyclotron which will produce PET scan medical isotopes. McMaster intends the facility to primarily be used for the development of new drugs for the early diagnosis of diseases such as cancer and Alzheimer’s. The facility will be able to produce imaging isotopes every day in the facility, where can be immediately delivered to a local hospital and used for the patients who need them most.
“Our Government has invested in innovation and knowledge infrastructure to set the foundation for economic prosperity,” said Gary Goodyear, Minister of State for Science and Technology. “This project has not only created jobs for people in our community, but it also provides infrastructure that will benefit McMaster University for years to come.”
In addition, the funding provided for extensive renovations and upgrades to the Nuclear Research Building, to accommodate and support new laboratories, research space and education for new faculty members, researchers and graduate students. The new McMaster building will play host to the Centre for Probe Development and Commercialization, a private sector government-funded not-for-profit enterprise whose funded goal is research, development and commercialization of new molecular imaging tools for disease treatment and diagnosis.
“This is a proud moment for our community, to have this world class upgraded facility to improve McMaster’s research and training for both today and the years to come,” said Ted McMeekin, MPP for Ancaster-Dundas-Flamborough-Westdale.
“Today’s announcement reaffirms our strong commitment to McMaster and its cutting- edge research,” said Sophia Aggelonitis, Minister of Revenue and MPP for Hamilton Mountain. “Not only did this investment bring jobs to our community, but it will improve the lives of people around the world.”
The funding also provided major maintenance in the McMaster Nuclear Reactor building, potentially extending the working life of this valuable research and education resource. MNR provides enough radioisotopes to treat 1000 cancer patients ever single week and is used by researchers all over the world who perform studies in geochronology, date ancient artifacts and study new kinds of crystals and materials. The reactor supports the mining and exploration sectors and tests the engine turbine blades of commercial aircraft in North America.
For more information, please contact:
T: 905-525-9140, ext 21212
Hamilton, Ontario, Canada – January 9, 2020 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that, following a successful U.S. Food and Drug Administration (FDA) inspection in July, CPDC’s site in Hamilton, Ontario, is cleared to ship products to the U.S. Justyna Kelly, interim
Hamilton, Ontario, December 3, 2019 – Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing as of today that the Company’s Board of Directors has appointed Justyna Kelly as Interim Chief Executive Officer effective immediately. Dr. Joe McCann will stay on as an Advisor
LONDON, Ontario – Led by researchers at Lawson Health Research Institute, a multi-centre registry trial is testing the use of a new imaging tracer, called a PSMA tracer, for early detection of recurrent prostate cancer. The registry gives patients access to a new type of imaging and will assess the impact on patient care. PSMA